➡️ .Ronan Kelly discusses the first overall survival results from CheckMate 577, which examined the use of adjuvant nivolumab in patients with resected #esophageal or #gastroesophageal junction cancer following neoadjuvant chemoradiotherapy. #ASCO25 buff.ly/GZh0Agf

❗For the first time in a phase 3 trial, a therapy has shown a statistically significant overall survival benefit in patients with unresectable locally advanced #PancreaticCancer. ➡️ Read more about the results of the #PANOVA3 trial presented at #ASCO25: buff.ly/Ka15KR9

📝 Recent study findings presented at #ASCO25 suggest that disitamab vedotin-based regimens could offer an effective and potentially #chemotherapy-sparing option for #HER2-expressing #GastricCancers. buff.ly/JutTmCg

📺 In this video, Dr. Erica Barnell discuses the recent inclusion of Geneoscopy's ColoSense in the National Comprehensive Cancer Network (NCCN) Guidelines for #ColorectalCancer screening. ❗She highlights how the inclusion reduces disparities in #ColorectalCancerScreening, and more: buff.ly/cR6E3pq

🔎In the final analysis of the INTRIGUE study, researchers reported on the OS, PFS, and safety of #ripretinib compared with #sunitinib in patients with advanced gastrointestinal stromal tumors: gioncologynow.com/post/intrigue-…

💭 Christopher Lieu, MD, CU Anschutz Medical Campus, shares his top liver-directed therapies for #metastatic #ColorectalCancer with liver involvement, including #SurgicalResection and transplant in select patients. 📺 Interested in learning more? Watch the video here: buff.ly/NJ65mTt

💪 A recent phase 3 randomized trial sought to determine if #exercise can improve the primary outcome of disease-free survival patients with resected #ColonCancer who had completed adjuvant #chemotherapy. 📖 Read more about the study's results here: buff.ly/BPIDL0S

➡️ The treatment landscape for gastroesophageal cancers has shifted away from systemic cytotoxic therapy alone since IO and molecular profiling have become available. 💬 Experts discuss the rapidly changing care environment in upper GI cancers: buff.ly/hXjEOGq

⏩ In this clip from our new roundtable series, Stacey Cohen, MD of Fred Hutch Cancer Center, comments on the National Comprehensive Cancer Network (NCCN) #CRC guidelines update, which noted that patients with PIK3CA-tumor mutations may benefit from adjuvant #aspirin therapy. 📺 Watch the full video here: buff.ly/CfD3UBS

🔬 Findings from the CheckMate 8HW trial have shown that #nivolumab plus #ipilimumab provides better progression-free survival rates as a first-line therapy compared with chemotherapy and nivolumab across all lines: buff.ly/LTr4PkD

🔎 A trial that compared the efficacy of #ramucirumab + #irinotecan against irinotecan monotherapy has found that both treatments provide a similar OS rate for patients with advanced #gastriccancer who experienced progression: buff.ly/qhHRDSc

👉 The treatment landscape for #gastroesophageal cancers has shifted since immunotherapy and molecular profiling have become available. ⭐ We recently spoke with Drs. Suneel Kamath MD and Sunnie Kim, MD about this rapidly changing landscape in upper GI cancers: buff.ly/hXjEOGq

Namrata (Neena) Vijayvergia MD of Fox Chase Cancer Center, recently joined a roundtable discussion on the current and future treatment considerations for advanced hepatocellular carcinoma (HCC). Watch on GI Oncology Now: bit.ly/4krLSfi

💊#Camrelizumab combined with concurrent #capecitabine and radiotherapy may provide survival outcomes in patients with resectable extrahepatic #cholangiocarcinoma and gallbladder cancer, according to a recent study: gioncologynow.com/post/radiation…

📺Watch our new interview with Scott Kopetz, where he explains how the BREAKWATER trial aligns with the FDA’s Project FrontRunner initiative by using early response rate data to support accelerated approval in BRAF V600E-mutated metastatic #colorectal cancer: gioncologynow.com/post/breakwate…

📺 In a new video interview, Laura Goff of Vanderbilt University Medical Center shares how she chooses between #atezolizumab + #bevacizumab and doublet immunotherapy regimens like #durvalumab + #tremelimumab for patients with advanced #hepatocellular carcinoma: buff.ly/6DhGieu

✅ In this video, Dr. Benjamin Weinberg, MD, FACP provides an in-depth recap of key #GICancer trials from #ASCO25, including the #MATTERHORN and #BREAKWATER trials. 💬 He highlights the data of each trial and how they impact the treatment landscape in GI oncology: buff.ly/pLIiWIN

🧬 The #KRAS gene is one of the most common oncogenic drivers in #GICancers Today, researchers have been expanding their efforts in targeting the gene and its mutations: buff.ly/zaXH1kB

❗Completed in 2024, phase 3 #ESOPEC trial demonstrated the efficacy of perioperative chemotherapy in combination with #FLOT #chemotherapy for patients with nonmetastatic esophageal #adenocarcinoma. ➡️ Read more about the results here: buff.ly/24FNW5W

🔬 Christopher Lieu, MD, CU School of Medicine, breaks down the impactful #GICancer studies presented at #ASCO25, including #MATTERHORN, #CHALLENGE, and #BREAKWATER. ⏩ Watch the full video here: buff.ly/7SK6KAg